SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: A PET study

Psychopharmacology

Volumn 226, Issue 1, 2013, Pages 147-153

  Takano, Akihiro ^a   Halldin, Christer ^a   Farde, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antidepressant; Brain imaging; Neurotransmission; Noradrenergic; Serotonin

Indexed keywords

CARBON 11; FLUORODEOXYGLUCOSE F 18; MILNACIPRAN; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; VENLAFAXINE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; HAPLORHINI; IN VIVO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL;

ANIMALS; BRAIN; CYCLOHEXANOLS; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MACACA FASCICULARIS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOLIGAND ASSAY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84877101375     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2901-z     Document Type: Article

References (33)

1. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880
2. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH (2006) Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318:657-665
3. DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L, Kharidia J, Robertson B, Mann JJ, Parsey RV (2007) SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J Nucl Med 52:1150-1155
4. 11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696-708
5. Farde L, Hall H, Ehrin E, Sedvall G (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231:258-261
6. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
7. Farde L, Wiesel FA, Nordstrom AL, Sedvall G (1989b) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 99(Suppl):S28-S31
8. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Rudaz S, Veuthey JL, Bertschy G (2004) Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol 59:883-891
9. 11)C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synapse 58:173-183
10. Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E (2006) The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 39:121-127
11. Higuchi H, Yoshida K, Takahashi H, Naito S, Kamata M, Ito K, Sato K, Tsukamoto K, Shimizu T, Nakanishi M, Hishikawa Y (2003) Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Hum Psychopharmacol 18:255-259
12. Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen K, Neuvonen PJ, Laine K (2008) Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther 83:342-348
13. 11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl) 113:149-156
14. Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, Perry KW, Bymaster FP (2003) Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45:935-944
15. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. NeuroImage 4:153-158
16. Lee CM, Farde L (2006) Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 27:310-316
17. Machado M, Einarson TR (2010) Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther 35:177-188
18. 11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835
19. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM (1996) Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41:149-156
20. 11C]raclopride. J Psychopharmacol 16:195-199
21. Schou M, Halldin C, Pike VW, Mozley PD, Dobson D, Innis RB, Farde L, Hall H (2005) Post-mortem human brain autoradiography of the norepinephrine transporter using (S, S)-[18 F]FMeNER-D2. Eur Neuropsychopharmacol 15:517-520
22. Schou M, Halldin C, Sovago J, Pike VW, Hall H, Gulyas B, Mozley PD, Dobson D, Shchukin E, Innis RB, Farde L (2004) PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 53:57-67
23. Sekine M, Arakawa R, Ito H, Okumura M, Sasaki T, Takahashi H, Takano H, Okubo Y, Halldin C, Suhara T (2010) Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S, S)-[18 F]FMeNER-D2. Psychopharmacology (Berl) 210:331-336
24. Seneca N, Gulyas B, Varrone A, Schou M, Airaksinen A, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis RB, Halldin C (2006) Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S, S)-[18 F]FMeNER-D2. Psychopharmacology (Berl) 188:119-127
25. Swanson LW, Hartman BK (1975) The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J Comp Neurol 163:467-505
26. Takano A, Gulyas B, Varrone A, Maguire RP, Halldin C (2009) Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S, S)-[(18)F]FMeNER-D (2). Eur J Nucl Med Mol Imaging 36:1308-1314
27. Takano A, Nag S, Gulyas B, Halldin C, Farde L (2011) NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. Psychopharmacology (Berl) 216:279-286
28. Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, Ikoma Y, Tanada S, Suhara T (2006) A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 185:395-399
29. Thase ME (2008) Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull 41:58-85
30. Troy SM, Lucki I, Peirgies AA, Parker VD, Klockowski PM, Chiang ST (1995) Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 35:410-419
31. Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L (2009) Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 36:1639-1650
32. Watson (2000) New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci 47:1587-1594
33. Zeng Z, Chen TB, Miller PJ, Dean D, Tang YS, Sur C, Williams DL Jr (2006) The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites. Nucl Med Biol 33:555-563